Is prescription decrease of Twynsta, a leading hypertension treatment, temporary?
Sales of ‘Twynsta(Boehringer Ingelheim, Yuhan Corporation),’ a hypertension treatment which became a KRW 80 billion leading product based on its product and sales power in the fever of complex drugs, have drawn a downward curve.
The phenomenon was analyzed have the influence of causes, such as a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
